Comparison 4. Adverse events: anti‐vascular endothelial growth factor (anti‐VEGF) versus control.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Systemic serious adverse events	4	508	Risk Ratio (M‐H, Fixed, 95% CI)	4.50 [0.60, 33.99]
2 Ocular serious adverse events	4	508	Risk Ratio (M‐H, Fixed, 95% CI)	1.82 [0.23, 14.71]